RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, is featured in a recent Cantor Fitzgerald research brief. Noting that the stock “looks even more interesting post solid quarter and ahead of potential strategic acquisition,” the research brief reiterated its previous Overweight (“OW”) rating and 12-month price target of $6 for RVL Pharmaceutical shares, stating that RVLP’s commercial opportunities continue to be underappreciated and that upward earnings estimate revisions should drive the stock higher. The brief noted that RVLP’s prescription eye drop, UPNEEQ 0.1%, had been selected the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty annual beauty awards, and that the company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden RVLP’s portfolio and leverage the field force investment.
“RVLP said it is in advanced discussions with certain companies that it could potentially partner with or acquire to support growth and integrate into its infrastructure with meaningful synergies,” stated the Cantor Fitzgerald report. “RVLP [also] reported second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, year over year, respectively. RVLP highlighted its lower baseline of operating expenses. It streamlined its operating expenses to extend its cash runway, optimize its marketing mix and support strategic business development. This streamlining had a modest unfavorable impact on sales during the quarter. And at 6/30/23, the company had cash and cash equivalents of $19.2 million and senior secured indebtedness with aggregate principal maturities of $70.7 million.”
To view the full press release, visit https://ibn.fm/B1Eph
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first nonsurgical treatment option approved by the FDA for acquired blepharoptosis. For additional information about this company, please visit www.RVLPharma.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment